ENFUEGO THERAPEUTICS
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. The company was founded by Chad Pecot in 2019 and is headquartered in Pittsboro, North Carolina.
ENFUEGO THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-02-01
Address:
Pittsboro, North Carolina, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
615-305-3955
Current Employees Featured
Founder
More informations about "Enfuego Therapeutics"
Enfuego Therapeutics Company Profile 2024: Valuation, Funding ...
Enfuego Therapeutics General Information Description. Operator of a biotech company intended to treat lung, pancreatic and colon cancers. The company is developing RNA interference …See details»
EnFuego Therapeutics - LinkedIn
EnFuego Therapeutics | 403 followers on LinkedIn. EnFuego Therapeutics is pioneering tumor-selective, mutant-specific RNAi molecules to solve cancer’s greatest challenges.See details»
Enfuego Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Enfuego Therapeutics Inc. of Pittsboro, NC. Get the latest business insights from Dun & Bradstreet.See details»
Enfuego Therapeutics - Crunchbase
Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. Search Crunchbase. Start Free Trial . …See details»
Enfuego Therapeutics Inc. - VentureRadar
Enfuego Therapeutics' novel RNA interference-(RNAi)-based and antisense oligo therapeutics are intended to treat cancer. We’re going after the big players in cancer, trying to develop drugs …See details»
Firm - SBIR
EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi)-based therapeutics. RNAi is particularly …See details»
Enfuego Therapeutics Inc. | North Carolina Biotech Center
Enfuego Therapeutics Inc. Enfuego Therapeutics Inc. Enfuego Therapeutics is developing novel RNA interference-(RNAi)-based and antisense oligo therapeutics. Company Location. 5151 …See details»
Enfuego Therapeutics - Contacts, Employees, Board Members
Organization. Enfuego Therapeutics . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Enfuego Therapeutics has …See details»
Enfuego Therapeutics - Products, Competitors, Financials, …
Enfuego Therapeutics is developing novel RNA interference-(RNAi)-based and antisense oligo therapeutics. Use the CB Insights Platform to explore Enfuego Therapeutics's full profile. …See details»
Chad Pecot - University of North Carolina at Chapel Hill …
I'm the founder and CEO of EnFuego Therapeutics, which is developing therapeutics to… · Experience: University of North Carolina at Chapel Hill · Education: University of Miami, Miller School ...See details»
Development of EFTX-001 to target KRAS mutations in cancer
EnFuego Therapeutics, Inc. to address the growing number of “undruggable” targets in cancer by using RNA interference (RNAi)-based therapeutics. RNAi is attractive because it enables …See details»
Chad Pecot: EnFuego Therapeutics is making a new generation of …
Oct 6, 2024 Chad Pecot, CEO of EnFuego Therapeutics, shared on X: ”Coming out of ‘stealth mode’ today with my hair on fire. EnFuego Therapeutics is making a new generation of RNA …See details»
Cancer survivor, UNC professor, and now, startup founder
Apr 9, 2021 Before launching EnFuego Therapeutics, Pecot wanted to understand what other startup founders did to be successful and what happened when they weren’t successful. He …See details»
UNC Innovation & Entrepreneurship - Innovate Carolina
Mar 16, 2020 In launching EnFuego Therapeutics, Pecot used innovation and entrepreneurship resources available at Carolina to develop his startup journey, including KickStart Venture …See details»
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
Itself to be widely regarded as “undruggable”. EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi) …See details»
Chad Pecot - Founder and CEO @ Enfuego Therapeutics
Primary Organization . Enfuego Therapeutics . Location Chapel Hill, North Carolina, United States; Regions Research Triangle ... Number of Current Jobs 1. Chad Pecot is the Founder …See details»
A patient’s decision adds immeasurably to knowledge about how …
Mar 15, 2022 Pecot is the founder of EnFuego Therapeutics, Inc. and holds equity in the company. No other authors have a declared conflict of interest., , , , Bringing together …See details»
Development of EFTX-001 to target KRAS mutations in cancer
Jun 1, 2020 We have established a C Corporation, EnFuego Therapeutics, Inc. to address the growing number of ?undruggable? targets in cancer by using RNA interference (RNAi)-based …See details»
Silencing of Oncogenic KRAS by Mutant-Selective Small …
A .gov website belongs to an official government organization in the United States . Secure .gov websites use HTTPS ... and C.V.P. hold intellectual property interests and/or an issued U.S. …See details»